Allergy

>

Latest News

Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose / image credit: ©New Africa/AdobeStock
Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose

March 28th 2025

Your daily dose of the clinical news you may have missed.

Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study / image credit ©Andrey Popov/AdobeStock
Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study

March 26th 2025

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

March 24th 2025

Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis / image credit ©tashatuvango/stock.adobe.com
Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis

March 18th 2025

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose / image credit: ©New Africa/AdobeStock
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose

March 17th 2025

Latest CME Events & Activities

Community Practice Connections™: Navigating a New Era of Food Allergy Management

View More

<123
© 2025 MJH Life Sciences

All rights reserved.